Antineoplastic agents from natural sources: Achievements and future directions

Expert Opinion on Investigational Drugs

Volumn 9, Issue 12, 2000, Pages 2783-2797

  Cragg, G M ^a   Newman, D J ^a  

^a Fairview Center   (United States)

Author keywords

Cancer chemotherapy; Natural products; Pharmacophores

Indexed keywords

7 HYDROXYSTAUROSPORINE; 9 AMINOCAPTOTHECIN; ANTINEOPLASTIC AGENT; B 1793; B 1939; BRYOSTATIN 1; CAPECITABINE; CEP 751; CRYPTOPHYCIN 1; CRYPTOPHYCIN 52; CRYPTOPHYCIN DERIVATIVE; DOCETAXEL; DOLASTATIN 10; EPOTHILONE A; EPOTHILONE B; ETOPOSIDE; FLAVOPIRIDOL; GEMCITABINE; HYCAMPTIN; IRINOTECAN; MIDOSTAURIN; NATURAL PRODUCT; STAUROSPORINE; TENIPOSIDE; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VINBLASTINE; VINCRISTINE; VINFLUNINE;

ACTINOBACTERIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BRYOZOA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHROMOBACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOBACTERIUM; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MARINE ENVIRONMENT; MOLLUSC; MOUSE; MYXOCOCCALES; NONHUMAN; NOSTOC; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLANT; REVIEW; SPONGE (PORIFERA); STREPTOMYCES; WORM;

EID: 0033659280     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.12.2783     Document Type: Review

References (88)

1. Natural products in drug discovery and development
2. The influence of natural products on drug discovery
3. Ethnobotany and drug discovery: The experience of the US national cancer institute
4. Plant-derived anticancer agents currently in clinical use or in clinical trials
5. The Taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents
6. Docetaxel
7. Role of plants in the national cancer institute drug discovery and development program
8. Promising new agents under development by the division of cancer treatment, diagnosis and centers of the national cancer institute
9. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis
10. The discovery of marine natural products with therapeutic potential
11. Marine natural products
12. Speciation of cone snails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns
13. Bryostatin-from bryozoan to cancer drug
14. Identification of sibling species of the bryozoan Bugula neritina that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont 'Candidatus Endobugula sertula'
15. Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis
16. Antitumor compounds from tunicates
17. Biomedical potential of marine natural products
18. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove
19. The dolastatins, a family of promising antineoplastic agents
20. Symplostatin 2: A dolastatin 13 analogue from the marine cyanobacterium Symploca bydnoides
21. Coral reefs, forests and thermal vents: The worldwide exploration of nature for novel antitumor agents
22. Discovery and sustainable supply of marine natural products as drugs, industrial compounds and agrochemicals: Chemical ecology, genetics, aquaculture and cell culture
23. The discovery and development of marine compounds with pharmaceutical potential
24. Highly potent in vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogs of halichondrin B
25. Synthetic macrocyclic ketone analogs of halichondrin B: Structure-activity relationships
26. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol
27. Antimitotic diterpenes from Erythropodium caribaeorum test pharmacophore models for microtubule stabilization
28. The coral-derived natural products eleutherobin and sarcodictyins A and B: Effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site
29. A common pharmacophore for epithilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
30. Isolation and structure of spongiastatin 1
31. Interphylal product splicing: The first total syntheses of cephalostatin 1, the North hemisphere of ritterazine G and the highly active hybrid analogue, ritterostatin GN1N
32. Antineoplastic agents, 120. Pancratium Littorale
33. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: A new generation of anti-cancer agents for the new century?
34. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action
35. Chemical biology of epothilones
36. Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends
37. Mother nature's pharmacy: A source of novel chemical structures
38. Current NCI preclinical antitumor screening in vivo. Results of tumor panel screening, 1976-1982 and future directions
39. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen
40. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
41. 'Triangular Privity' - A working paradigm for the equitable sharing of benefits from biodiversity research and development
42. Natural product drug discovery and development new perspectives on international collaboration
43. Rival genome sequencers celebrate a milestone together
44. Finally, the book of life and instructions for navigating it
45. New treatment for CML could be model for molecular target-based therapeutics
46. Small-molecule inhibitors of the cell cycle
47. Preclinical and clinical development of cyclin-dependent kinase modulators
48. Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine inhibitors with hypervalent iodine reagents
49. Ras farnesyltransferase: A new therapeutic target
50. Natural products as angiogenesis inhibitors
51. Antiangiogenic agents
52. Small molecule inhibitors of tumor promoted angiogenesis, including protein tyrosine kinase inhibitors
53. Tumor angiogenesis-new drugs on the block
54. Ecology of deep-sea hydrothermal vent communities: A review
55. Rapid growth at deep sea vents
56. Plant-derived natural products in drug discovery and development. An overview
57. Major microbial diversity initiative recommended
58. Molecular biological access to the chemistry of unknown soil microbes: A new frontier for natural products
59. Extremophiles
60. Life at the freezing point
61. Finding and using hyperthermophilic enzymes
62. Microbial polyketide synthases: More and more prolific
63. Dissecting and exploiting intermodular communication in polyketide synthases
64. Modular enzymes
65. The gene calC encodes for a non-heme iron metalloprotein responsible for calicheamicin self-resistance in Micromonospora
66. Genes for production of the enediyne antitumor antibiotic C-1027 in Streptomyces globisporus are clustered with the cagA gene that encodes the C-1027 apoprotein
67. The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90
68. Drug industry looks to the lab instead of rainforest and reef
69. Synthesis of the first members of a new class of biologically active bryostatin analogues
70. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743
71. Four types of natural products that stabilize cell microtubules share structural features
72. Solid and solution phase synthesis and biological evaluation of combinatorial sarcodictyin libraries
73. Synthesis and biological activity of sarcodictyins
74. Total synthesis of sarcodictyins A and B
75. Total synthesis of eleutherobin and eleuthosides A and B
76. Chemical genetics resulting from a passion for synthetic organic chemistry
77. Targeted toxins
78. Enediyne research continues apace
79. Eradication of large colon tumor xenografts by targeted delivery of maytansanoids
80. Phase I clinical and pharmacokinetic study of PK1 [N-(2- hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates
81. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine
82. Antibody-enzyme conjugates for cancer therapy
83. Actinomycetes